Chronic Kidney Disease(CKD), Uncontrolled Hypertension
Conditions
Brief summary
Chronic kidney disease (CKD) is a major public health issue worldwide. Hypertension is the first risk factor in patients with CKD for mortality, cardiovascular disease and end-stage renal disease. It's now well established that lowering blood pressure (BP) reduces renal and cardiovascular complications in this high-risk population. In the general population, in addition to lifestyle interventions, the strategy to initiate and escalate a BP-lowering drug treatment is well described. The drug therapies recommended to achieve optimal BP control in the general population are the following: blockers of the renin-angiotensin system (angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB)), diuretics (thiazides and thiazide-like diuretics), and calcium channel blockers. For patients with CKD, the guidelines advise to start the BP-lowering agent with ACEi or ARB, but then, there is no strong evidence to support the preferential use of any particular agent in controlling BP and the results of clinical trials are discordant. In the NephroTest cohort, a French cohort of patients with CKD stage 1 to 5, among 2015 patients, 1782 had hypertension, only 54% had a diuretic and 44% had uncontrolled hypertension. In this cohort, extracellular fluid (ECF) overload was an independent determinant of hypertension, uncontrolled hypertension and apparent treatment resistant hypertension. In the same cohort, ECF overload was independently associated with end-stage kidney disease and death. Our hypothesis is that patients with CKD and uncontrolled hypertension are fluid overloaded and that the second line of treatment after an ACEi or an ARB should be a diuretic. We hypothesize that a specific algorithm to lower BP in patients with moderate to severe CKD based on diuretics will be more effective in term of cardiovascular event, mortality and evolution to end-stage kidney disease as compared to standard of care.
Interventions
DRUGAntihypertensive algorithm
Antihypertensive algorithm based on diuretics agents
DRUGStandard of care
standard of care management for antihypertensive therapy intensification
Sponsors
University Hospital, Tours
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Masking description
The very nature of the intervention assessed prevents any form of blinding, neither for care providers, nor for patients. However, the primary outcome is a composite outcome of events which we plan to adjudicate. As a consequence, the primary outcome will be blindly assessed.
Intervention model description
Cluster randomized controlled
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Male or female \>=18 years with a clinical frailty score ≤5 for patient aged over 80 * Advanced or moderate chronic kidney disease (eGFR 15 to 44.9 mL/min/1.73m² using CKD-EPI formula) * Arterial hypertension treated with at least one blood pressure lowering drug therapy among blockers of the renin-angiotensin system (ACEi or ARB), at the maximal posology tolerated by the patients stable since at least one month. Other blood pressure lowering drug therapies are tolerated in combination with or in the event of intolerance to ACE inhibitors or ARBs. * Uncontrolled office BP * Uncontrolled office BP (\>140 and/or 90 mmHg) confirmed by home blood pressure monitoring (\>135 and/or 85 mmHg) or Day-time Ambulatory Blood Pressure Monitoring * Participant covered by or entitled to social security * Written informed consent obtained from the participant
Exclusion criteria
* Patient following any measures of legal presentation * Pregnant or breastfeeding woman * woman of childbearing without a highly effective contraceptive measure (combined or progestogen-only hormonal contraception associated with inhibition of ovulation, intrauterine device or intrauterine hormone-releasing system) * Clinical signs of hypovolemia * Symptomatic orthostatic hypotension * Hyponatremia (\<130 mmol/L) * Dyskalemia (\<3,5 mmol/L or \>5,5 mmol/L) * Major adverse cardiovascular event during the last three months: myocardial infarction, heart failure hospitalization, stroke * Current medical history of cancer requiring chemotherapy * Solid organ transplantation * Two or more diuretic agents (loop diuretic, thiazides and thiazide-like diuretics) * Mineralocorticoid receptor antagonists * Autosomal dominant polycystic kidney disease treated with Tolvaptan * Contraindication to diuretics involved in the algorithm * Severe heart failure (NYHA III\_IV) * Cirrhosis Child B-C
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| End stage kidney disease | Up to 36 months | The primary endpoint is a time to event outcome, considering the following composite endpoint: * End stage kidney disease * eGFR decline of at least 40% * Cardiovascular events among myocardial infarction, heart failure, hospitalization and stroke * All cause mortality |
| eGFR decline of at least 40% | Up to 36 months | The primary endpoint is a time to event outcome, considering the following composite endpoint: * End stage kidney disease * eGFR decline of at least 40% * Cardiovascular events among myocardial infarction, heart failure, hospitalization and stroke * All cause mortality |
| Cardiovascular events | Up to 36 months | The primary endpoint is a time to event outcome, considering the following composite endpoint: * End stage kidney disease * eGFR decline of at least 40% * Cardiovascular events among myocardial infarction, heart failure, hospitalization and stroke * All cause mortality |
| All cause mortality | Up to 36 months | The primary endpoint is a time to event outcome, considering the following composite endpoint: * End stage kidney disease * eGFR decline of at least 40% * Cardiovascular events among myocardial infarction, heart failure, hospitalization and stroke * All cause mortality |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Time to end-stage kidney disease | Up to 36 months | All components of the composite endpoint will be assessed separately |
| Time to eGFR decrease of at leat 40% | Up to 36 months | All components of the composite endpoint will be assessed separately |
| Time to the first cardiovascular event among myocardial infarction, heart failure, hospitalization and stroke | Up to 36 months | All components of the composite endpoint will be assessed separately |
| All-cause mortality | Up to 36 months | All components of the composite endpoint will be assessed separately |
| Change from baseline in blood pressure | From baseline and up to 36 months | Systolic and diastolic blood pressure at months 3 and 6 then every 6 months (home blood pressure monitoring and office blood pressure measurement), |
| Proportion of patients with controlled blood pressure | 24 months | Proportion of patients with controlled blood pressure at 2 years (PA\< 135/85mmHg with home blood pressure monitoring) |
| Change from baseline in glomerular filtration rate | From baseline and up to 36 months | Change from baseline in glomerular filtration rate estimated by CKD-EPI formula at months 3 and 6 then every 6 months |
| Change from baseline in proteinuria (g/d) or proteinuria /creatinuria (g/g) | From baseline and up to 36 months | Change from baseline in proteinuria (g/d) or proteinuria /creatinuria (g/g) at months 3 and 6 then every 6 months |
| Proportion of patients who used at least one diuretic | Up to 36 months | — |
| Change from baseline in quality of life | From baseline and up to 36 months | Change from baseline in quality of life assessed by PROMIS-29 survey each year |
Countries
France
Contacts
CONTACTBénédicte Sautenet, MD
PRINCIPAL_INVESTIGATORBénédicte Sautenet, MD
University Hospital, Tours
Outcome results
None listed